PRELOAD PRELOAD PRELOAD PRELOAD PRELOAD

Investors

Press Releases

All Releases
View Summary BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Brazil for Treatment of Morquio A Syndrome
Dec 10, 2014
PDF 59.2 KB Add to Briefcase
View Summary FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB (Sanfilippo Syndrome Type B)
Dec 10, 2014
PDF 11.0 KB Add to Briefcase
View Summary BioMarin to Highlight Breadth of Innovative Development Pipeline at Analyst and Investor Day on December 10th in New York
Dec 9, 2014
PDF 10.1 KB Add to Briefcase
View Summary BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Australia for Treatment of Morquio A Syndrome
Dec 7, 2014
PDF 59.3 KB Add to Briefcase
View Summary BioMarin to Host Analyst and Investor Day on December 10th in New York
Dec 3, 2014
PDF 8.5 KB Add to Briefcase
View Summary BioMarin and Prosensa Holding N.V. Reach Agreement on Intended Public Offer for 100% of Prosensa's Outstanding Stock; Will Add Duchenne Muscular Dystrophy Products to Rare-Disease Portfolio
Nov 24, 2014
PDF 21.1 KB Add to Briefcase
View Summary BioMarin to Attend Upcoming Investor Conferences
Nov 19, 2014
PDF 7.5 KB Add to Briefcase
View Summary Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Credit Suisse 2014 Healthcare Conference
Nov 4, 2014
PDF 7.4 KB Add to Briefcase
View Summary BioMarin Announces Third Quarter 2014 Financial Results
Oct 23, 2014
PDF 40.5 KB Add to Briefcase
View Summary BioMarin to Host Third Quarter 2014 Financial Results Conference Call and Webcast on Thursday, October 23 at 4:30pm ET
Oct 8, 2014
PDF 8.6 KB Add to Briefcase
View Summary FDA Receives Paragraph IV Notice Letter for KUVAN(R) (sapropterin dihydrochloride) Tablets
Sep 24, 2014
PDF 9.3 KB Add to Briefcase
View Summary BioMarin to Attend Upcoming Investor Conferences
Sep 23, 2014
PDF 7.5 KB Add to Briefcase
View Summary BioMarin Named by CenterWatch as One of the Fastest Developers of Medicines
Sep 15, 2014
PDF 9.6 KB Add to Briefcase
View Summary BioMarin to Attend Upcoming Investor Conferences in London
Sep 10, 2014
PDF 7.1 KB Add to Briefcase
View Summary BioMarin to Present at Upcoming Investor Conferences
Aug 19, 2014
PDF 7.6 KB Add to Briefcase
View Summary BioMarin Announces Second Quarter 2014 Financial Results
Jul 30, 2014
PDF 41.6 KB Add to Briefcase
View Summary BioMarin Sells Priority Review Voucher for $67.5 Million
Jul 30, 2014
PDF 8.4 KB Add to Briefcase
View Summary Sarah Cannon Research Institute UK and BioMarin Collaborate on EMBRACA Clinical Study in Hereditary Breast Cancer With BRCA Mutation
Jul 23, 2014
PDF 13.4 KB Add to Briefcase
View Summary BioMarin to Host Second Quarter 2014 Financial Results Conference Call and Webcast on Wednesday, July 30 at 4:30pm ET
Jul 9, 2014
PDF 8.5 KB Add to Briefcase
View Summary BioMarin Announces Health Canada Approval of VIMIZIM (elosulfase alfa) for the Treatment of Morquio A Syndrome
Jul 7, 2014
PDF 15.0 KB Add to Briefcase
Showing 1-20 of 315 Page: 1 2 3 4 5 ... 16  Next 20
Add to Briefcase = add release to Briefcase